Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013521 | 1.00 | PNP (0.61) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5981918 | 1.00 | PNP (0.61) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL767194 | 1.00 | PNP (0.61) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL855722 | 0.88 | PNP (0.64) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL10438039 | 0.88 | PNP (0.64) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982169 | 0.87 | LMNA (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1470361 | 0.87 | LMNA (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5790133 | 0.87 | LMNA (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL15623873 | 0.87 | LMNA (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982273 | 0.87 | LMNA (0.76) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114088626-A | Method and detection system for identifying pasteurized milk | 国家食品安全风险评估中心 | 2022-02-25 | — | — | CN | claimed |
| US-11835499-B2 | Methods of quantifying methylglyoxal-induced nucleic acid adducts | CITY OF HOPE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220331273-A1 | METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEDG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEDG | CITY OF HOPE (US) | 2022-10-20 | — | — | US | disclosed |
| CN-114088626-B | Method and detection system for identifying pasteurized milk | 国家食品安全风险评估中心 | 2022-08-26 | — | — | CN | disclosed |
| CN-114088626-A | Method and detection system for identifying pasteurized milk | 国家食品安全风险评估中心 | 2022-02-25 | — | — | CN | disclosed |
| US-11179361-B2 | Methods of quantifying N2-(1-carboxyethyl)-2′-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG | CITY OF HOPE (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200363381-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2020-11-19 | — | — | US | disclosed |
| WO-2019152728-A1 | METHODS OF QUANTIFYING METHYLGLYOXAL-INDUCED NUCLEIC ACID ADDUCTS | CITY OF HOPE (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20180338939-A1 | METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEDG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEDG | CITY OF HOPE | 2018-11-29 | — | — | US | disclosed |
| EP-0716604-B1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2005-03-16 | — | — | EP | disclosed |
| US-6114513-A | MEDICAL DIAGNOSIS; TRANSFER ACROSS CELL MEMBRANES | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-5852182-A | Thiol-derivatized oligonucleosides | ISIS PHARMACEUTICALS INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5578718-A | Thiol-derivatized nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |